Dr. Oaknin on the GARNET Study in Endometrial Cancer

Ana Oaknin, MD
Published: Thursday, Mar 21, 2019



Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the phase I/II GARNET trial in patients with endometrial cancer.

In the phase I/II trial, investigators examined the anti–PD-1 monoclonal antibody, dostarlimab (TSR-042), in patients with solid tumors. Results from the cohort of patients with recurrent or advanced microsatellite instability-high (MSI-H) and microsatellite stable (MSS) endometrial cancer were presented at the 2019 Annual SGO Meeting, says Oaknin.

To be eligible for enrollment, patients had to have recurrent or advanced endometrial cancer and have already progressed on or after a platinum-based chemotherapy. Approximately half of patients had received ≥2 prior lines of chemotherapy, representing a heavily pretreated patient population with a historically poor prognosis, says Oaknin. Data showed that patients treated with dostarlimab had an objective response rate of almost 30% . Moreover, these responses were durable—irrespective of MSI-H or MSS status.
SELECTED
LANGUAGE


Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the phase I/II GARNET trial in patients with endometrial cancer.

In the phase I/II trial, investigators examined the anti–PD-1 monoclonal antibody, dostarlimab (TSR-042), in patients with solid tumors. Results from the cohort of patients with recurrent or advanced microsatellite instability-high (MSI-H) and microsatellite stable (MSS) endometrial cancer were presented at the 2019 Annual SGO Meeting, says Oaknin.

To be eligible for enrollment, patients had to have recurrent or advanced endometrial cancer and have already progressed on or after a platinum-based chemotherapy. Approximately half of patients had received ≥2 prior lines of chemotherapy, representing a heavily pretreated patient population with a historically poor prognosis, says Oaknin. Data showed that patients treated with dostarlimab had an objective response rate of almost 30% . Moreover, these responses were durable—irrespective of MSI-H or MSS status.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x